<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-10-20" updated="2019-12-02">
  <drugbank-id primary="true">DB11692</drugbank-id>
  <name>Pavinetant</name>
  <description>Pavinetant has been used in trials studying the basic science and treatment of Safety and Schizophrenia.</description>
  <cas-number>941690-55-7</cas-number>
  <unii>3U471ZVC5K</unii>
  <average-mass>459.56</average-mass>
  <monoisotopic-mass>459.161662851</monoisotopic-mass>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.</description>
    <direct-parent>Phenylquinolines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Quinolines and derivatives</class>
    <subclass>Phenylquinolines</subclass>
    <alternative-parent>Aminosulfonyl compounds</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic sulfonamides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organosulfonamides</alternative-parent>
    <alternative-parent>Phenylpropanes</alternative-parent>
    <alternative-parent>Phenylpyridines</alternative-parent>
    <alternative-parent>Pyridinecarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Quinoline carboxamides</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Vinylogous amides</alternative-parent>
    <substituent>2-phenylpyridine</substituent>
    <substituent>Aminosulfonyl compound</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic sulfonic acid amide</substituent>
    <substituent>Organic sulfonic acid or derivatives</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organosulfonic acid amide</substituent>
    <substituent>Organosulfonic acid or derivatives</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Phenylpropane</substituent>
    <substituent>Phenylquinoline</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridine carboxylic acid or derivatives</substituent>
    <substituent>Quinoline-4-carboxamide</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Sulfonyl</substituent>
    <substituent>Vinylogous amide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="inn">pavinetant</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Quinolines</category>
      <mesh-id>D011804</mesh-id>
    </category>
    <category>
      <category>Receptors, Neurokinin-3, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sulfones</category>
      <mesh-id>D013450</mesh-id>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.52</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.33e-04 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.28</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>459.56</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>459.161662851</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC[C@H](NC(=O)C1=C(NS(C)(=O)=O)C(=NC2=CC=CC=C12)C1=CC=CC=C1)C1=CC=CC=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C26H25N3O3S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>QYTBBBAHNIWFOD-NRFANRHFSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>88.16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>128.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>49.06</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>5.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>0.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>140478</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>23649245</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347828057</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>28189763</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50180193</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pavinetant</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3545233</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0002371</id>
      <name>Neuromedin-K receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38968</ref-id>
            <pubmed-id>24525659</pubmed-id>
            <citation>Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ: The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study. J Clin Psychopharmacol. 2014 Apr;34(2):199-204. doi: 10.1097/JCP.0000000000000071.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P29371" source="Swiss-Prot">
        <name>Neuromedin-K receptor</name>
        <general-function>Tachykinin receptor activity</general-function>
        <specific-function>This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K &gt; substance K &gt; substance P.</specific-function>
        <gene-name>TACR3</gene-name>
        <locus>4q25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>85-107
118-139
160-181
202-222
246-270
300-321
335-359</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.61</theoretical-pi>
        <molecular-weight>52201.35</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11528</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TACR3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M89473</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>362</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>362</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29371</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NK3R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Neurokinin B receptor</synonym>
          <synonym>NK-3 receptor</synonym>
          <synonym>NK-3R</synonym>
          <synonym>NK3R</synonym>
          <synonym>NKR</synonym>
          <synonym>TAC3R</synonym>
          <synonym>Tachykinin receptor 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016769|Neuromedin-K receptor
MATLPAAETWIDGGGGVGADAVNLTASLAAGAATGAVETGWLQLLDQAGNLSSSPSALGL
PVASPAPSQPWANLTNQFVQPSWRIALWSLAYGVVVAVAVLGNLIVIWIILAHKRMRTVT
NYFLVNLAFSDASMAAFNTLVNFIYALHSEWYFGANYCRFQNFFPITAVFASIYSMTAIA
VDRYMAIIDPLKPRLSATATKIVIGSIWILAFLLAFPQCLYSKTKVMPGRTLCFVQWPEG
PKQHFTYHIIVIILVYCFPLLIMGITYTIVGITLWGGEIPGDTCDKYHEQLKAKRKVVKM
MIIVVMTFAICWLPYHIYFILTAIYQQLNRWKYIQQVYLASFWLAMSSTMYNPIIYCCLN
KRFRAGFKRAFRWCPFIKVSSYDELELKTTRFHPNRQSSMYTVTRMESMTVVFDPNDADT
TRSSRKKRATPRDPSFNGCSRRNSKSASATSSFISSPYTSVDEYS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016770|Neuromedin-K receptor (TACR3)
ATGGCCACTCTCCCAGCAGCAGAAACCTGGATAGACGGGGGTGGAGGCGTGGGTGCAGAC
GCCGTGAACCTGACCGCCTCGCTAGCTGCCGGGGCGGCCACGGGGGCAGTTGAGACTGGG
TGGCTGCAACTGCTGGACCAAGCTGGCAACCTCTCCTCCTCCCCTTCCGCGCTGGGACTG
CCTGTGGCTTCCCCCGCGCCCTCCCAGCCCTGGGCCAACCTCACCAACCAGTTCGTGCAG
CCGTCCTGGCGCATCGCGCTCTGGTCCCTGGCGTATGGTGTGGTGGTGGCAGTGGCAGTT
TTGGGAAATCTCATCGTCATCTGGATCATCCTGGCCCACAAGCGCATGAGGACTGTCACC
AACTACTTCCTTGTGAACCTGGCTTTCTCCGACGCCTCCATGGCCGCCTTCAACACGTTG
GTCAATTTCATCTACGCGCTTCATAGCGAGTGGTACTTTGGCGCCAACTACTGCCGCTTC
CAGAACTTCTTTCCTATCACAGCTGTGTTCGCCAGCATCTACTCCATGACGGCCATTGCG
GTGGACAGGTATATGGCTATTATTGATCCCTTGAAACCCAGACTGTCTGCTACAGCAACC
AAGATTGTCATTGGAAGTATTTGGATTCTAGCATTTCTACTTGCCTTCCCTCAGTGTCTT
TATTCCAAAACCAAAGTCATGCCAGGCCGTACTCTCTGCTTTGTGCAATGGCCAGAAGGT
CCCAAACAACATTTCACTTACCATATTATCGTCATTATACTGGTGTACTGTTTCCCATTG
CTCATCATGGGTATTACATACACCATTGTTGGAATTACTCTCTGGGGAGGAGAAATCCCA
GGAGATACCTGTGACAAGTATCATGAGCAGCTAAAGGCCAAAAGAAAGGTTGTCAAAATG
ATGATTATTGTTGTCATGACATTTGCTATCTGCTGGCTGCCCTATCATATTTACTTCATT
CTCACTGCAATCTATCAACAACTAAATAGATGGAAATACATCCAGCAGGTCTACCTGGCT
AGCTTTTGGCTGGCAATGAGCTCAACCATGTACAATCCCATCATCTACTGCTGTCTGAAT
AAAAGATTTCGAGCTGGCTTCAAGAGAGCATTTCGCTGGTGTCCTTTCATCAAAGTTTCC
AGCTATGATGAGCTAGAGCTCAAGACCACCAGGTTTCATCCAAACCGGCAAAGCAGTATG
TACACCGTGACCAGAATGGAGTCCATGACAGTCGTGTTTGACCCCAACGATGCAGACACC
ACCAGGTCCAGTCGGAAGAAAAGAGCAACGCCAAGAGACCCAAGTTTCAATGGCTGCTCT
CGCAGGAATTCCAAATCTGCCTCCGCCACTTCAAGTTTCATAAGCTCACCCTATACCTCT
GTGGATGAATATTCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>tachykinin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyperosmotic salinity response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of uterine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tachykinin receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>